Sarepta TherapeuticsSRPT
SRPT
About: Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Employees: 1,314
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
26% more call options, than puts
Call options by funds: $278M | Put options by funds: $221M
8% more repeat investments, than reductions
Existing positions increased: 168 | Existing positions reduced: 155
6% less funds holding
Funds holding: 481 [Q2] → 451 (-30) [Q3]
6.82% less ownership
Funds ownership: 96.86% [Q2] → 90.04% (-6.82%) [Q3]
26% less capital invested
Capital invested by funds: $14.5B [Q2] → $10.7B (-$3.75B) [Q3]
34% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 88
50% less funds holding in top 10
Funds holding in top 10: 16 [Q2] → 8 (-8) [Q3]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
37%
downside
Avg. target
$164
38%
upside
High target
$202
70%
upside
10 analyst ratings
9 positive
90%
0 neutral
0%
1 negative
10%
HC Wainwright & Co. Mitchell Kapoor 25% 1-year accuracy 41 / 165 met price target | 37%downside $75 | Sell Reiterated | 19 Dec 2024 |
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 53%upside $182 | Overweight Maintained | 27 Nov 2024 |
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target | 70%upside $202 | Buy Maintained | 27 Nov 2024 |
Guggenheim Whitney Ijem 21% 1-year accuracy 8 / 39 met price target | 26%upside $150 | Buy Maintained | 7 Nov 2024 |
Baird Brian Skorney 29% 1-year accuracy 7 / 24 met price target | 62%upside $193 | Outperform Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 13 articles about SRPT published over the past 30 days
Positive
Reuters
16 hours ago
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Japanese drugmaker Nippon Shinyaku infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday.
Positive
Zacks Investment Research
1 day ago
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.
Neutral
Zacks Investment Research
1 day ago
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
Neutral
Business Wire
3 days ago
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4), or beta-sarcoglycanopathy. EMERGENE is a global study, and the primary endpoint is t.
Positive
Zacks Investment Research
3 days ago
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
Positive
Proactive Investors
1 week ago
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The FDA earlier this month published the draft guidance on its policies and procedures for the accelerated approval (AA) pathway for drugs for serious conditions that fulfil an unmet medical need.
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
The consensus price target hints at a 48% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
1 week ago
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
3 weeks ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in November 2024. The equity awards were approved in accordance with Nasdaq Lis.
Positive
Zacks Investment Research
3 weeks ago
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
Charts implemented using Lightweight Charts™